PEPTIDE

Dulaglutide (Trulicity)

Long-acting GLP-1 receptor agonist fused to Fc; ~5-day half-life via FcRn recycling. Approved for T2D and MACE reduction.

BIOGATE · GREEN | POSTERIOR 39.1% | MW 59670.0 | 31AA

SEQUENCE

HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG

Modifications: GLP-1 analog fused to IgG4 Fc fragment; weekly SC dosing

PDA-V1 chain of custody

Outer hash

172650-c21826525515264d9c16264f2f13264a7614264c091126475012264

Merkle root

446572-bd4365712a42656f9741656e0440656c713f656ade3e65694b3d6567b8

Inputs

99-d38e429ad38fd597d38b1c98d38caf95d387f696d3898993d384d09

TEE attestation

ecd1e39febd1e20ceed1e6c5edd1e532e8d1dd53e7d1dbc0ead1e079e9d1dee6

Living Outcome Oracle

± =17.1 ² =26.6 **P(success) = 39.1%**

95% CI [27.1%, 51.1%]

Seven-rule export gate

7 / 7 rules satisfied · audience: researcher · Full attestation set, raw posteriors, all hashes

- Grade A or B citation present on the core claim
- BioGate verdict is GREEN or AMBER (RED/BLACK refused)
- Jurisdiction permits the audience-appropriate use
- RWE summary attached when claim depends on outcome data
- Prediction-outcome pairs disclosed when posterior cited
- No human-use claim beyond cited indications
- COA registry lookup available for any synthesis claim

Citations

GRADE A — 2014 · Diabetes Care

Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes (AWARD-3)

Umpierrez G et al.

PMID 25137548